Kusuri Context Studio
Back to articles

What Does Japan’s Advisory Committee Review When a Class 1 OTC Medicine Is Reclassified?

OTC medicine boxes in Japan carry labels such as “Class 1 OTC medicine” or “Class 2 OTC medicine.” When a classification comes up for review, experts convened by the Ministry of Health, Labour and Welfare (MHLW) examine reports of side effects and how the medicine is used. A safety working group examines the evidence in detail. A subcommittee then deliberates on the classification in light of the working group’s assessment. Two examples show what information the experts consider.

Nasivin Medi, a nasal spray containing oxymetazoline and chlorpheniramine, moved from Class 1 to Class 2 on September 13, 2025. For loxoprofen, excluding topical preparations and products intended to relieve cold symptoms, the MHLW reported that its October 29, 2026 subcommittee meeting concluded that deliberations would continue at the next meeting. [Subcommittee minutes for the nasal spray · Notice of the nasal spray’s reclassification · Status of reclassification deliberations]

The nasal spray was reviewed when its post-marketing survey was complete. Loxoprofen was taken up through a process introduced in April 2026 that allows requests for reclassification to be submitted to the MHLW. [Subcommittee minutes for the nasal spray · How reclassification requests are accepted · Loxoprofen review materials]

What the full article covers
Using the nasal spray and loxoprofen cases, the article looks at the conditions for requesting reclassification, the data experts review, and the steps before the way a medicine is sold changes. It also compares the package inserts for three OTC pain relievers and gives examples of how to check existing conditions and possible interactions at the counter.

Continue on note

The full article is available in Japanese as a paid article on note.

Read the article on note